LY3009104

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

Arthritis, RheumatoidChronic Inflammatory DisorderHealthy ParticipantsHealthy VolunteerHealthy Volunteers

Phase 1

A Study of LY3009104(Baricitinib) for Healthy Subjects

CompletedNCT01247350

Eli Lilly and CompanyHealthy Volunteer

Start: 2010-11-30End: 2011-04-30Updated: 2018-04-13

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

CompletedNCT01299285

Eli Lilly and CompanyHealthy Volunteers

Start: 2011-02-28End: 2011-03-31Updated: 2017-06-08

A Relative Bioavailability and Food Effect Study of New Formulations

CompletedNCT01398475

Eli Lilly and CompanyArthritis, Rheumatoid, Chronic Inflammatory Disorder

Start: 2011-07-31End: 2011-09-30Updated: 2017-04-21

A Study of LY3009104 in Healthy Participants

CompletedNCT01536951

Eli Lilly and CompanyHealthy Participants

Start: 2012-02-29End: 2013-05-31Updated: 2017-06-06

Phase 2

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

CompletedNCT01185353

Eli Lilly and CompanyArthritis, Rheumatoid

Start: 2010-10-31End: 2014-03-31Updated: 2017-06-16

Related Papers

Applying Bias Correction Methods to Build Hybrid Controls Using Real‐World Patients for a Phase <scp>IIb</scp> Randomized Controlled Trial of Baricitinib for Rheumatoid Arthritis

Pharmaceutical Statistics2025-06-10

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.

2021-10-27107 citations

Novel quantitative digital image analysis methodology for assessment of inflammatory changes in MRI data in a post-hoc analysis of data acquired from a phase IIb study of baricitinib in patients with active rheumatoid arthritis.

2021-08-081 citations

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

Modern Rheumatology2019-02-2054 citations

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis

The Journal of Rheumatology2019-01-158 citations

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

The Journal of Rheumatology2018-09-15251 citations

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.

2018-02-2044 citations

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis

The Journal of Rheumatology2017-08-1567 citations

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

2014-11-27218 citations